Craft

Biofrontera

Stock Price

€2.6

2024-07-12

Market Capitalization

€984.5 K

2024-07-12

Revenue

€32.2 M

FY, 2023

Biofrontera Summary

Company Summary

Overview
Biofrontera is a biopharmaceutical company that specializes in the development and commercialization of dermatological medications and medical cosmetics. It offers Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis; BF-RhodoLED lamp, photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis, and Belixos, an over-the-counter line of skin care cosmetic products.
Type
Public
Status
Active
Founded
2012
HQ
Leverkusen, DE | view all locations
Website
http://biofrontera.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Hermann Lübbert

    Hermann Lübbert, CEO

    • Ludwig Lutter

      Ludwig Lutter, CFO

      LocationsView all

      1 location detected

      • Leverkusen, Nordrhein-Westfalen HQ

        Germany

        201 Hemmelrather Weg

      Biofrontera Financials

      Summary Financials

      Revenue (Q3, 2024)
      €3.5M
      Gross profit (Q3, 2024)
      €2.8M
      Net income (Q3, 2024)
      (€930.0K)
      Cash (Q3, 2024)
      €1.8M
      EBIT (Q3, 2024)
      (€956.0K)
      Enterprise value
      ($42.5K)

      Footer menu